Literature DB >> 12411319

Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow.

Wolf-K Hofmann1, Sven de Vos, Martina Komor, Dieter Hoelzer, William Wachsman, H Phillip Koeffler.   

Abstract

Gene patterns of expression in purified CD34(+) bone marrow cells from 7 patients with low-risk myelodysplastic syndrome (MDS) and 4 patients with high-risk MDS were compared with expression data from CD34(+) bone marrow cells from 4 healthy control subjects. CD34(+) cells were isolated by magnetic cell separation, and high-density oligonucleotide microarray analysis was performed. For confirmation, the expression of selected genes was analyzed by real-time polymerase chain reaction. Class membership prediction analysis selected 11 genes. Using the expression profile of these genes, we were able to discriminate patients with low-risk from patients with high-risk MDS and both patient groups from the control group by hierarchical clustering (Spearman confidence). The power of these 11 genes was verified by applying the algorithm to an unknown test set containing expression data from 8 additional patients with MDS (3 at low risk, 5 at high risk). Patients at low risk could be distinguished from those at high risk by clustering analysis. In low-risk MDS, we found that the retinoic-acid-induced gene (RAI3), the radiation-inducible, immediate-early response gene (IEX1), and the stress-induced phosphoprotein 1 (STIP1) were down-regulated. These data suggest that CD34(+) cells from patients with low-risk MDS lack defensive proteins, resulting in their susceptibility to cell damage. In summary, we propose that gene expression profiling may have clinical relevance for risk evaluation in MDS at the time of initial diagnosis. Furthermore, this study provides evidence that in MDS, hematopoietic stem cells accumulate defects that prevent normal hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411319     DOI: 10.1182/blood.V100.10.3553

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  60 in total

1.  Principled sure independence screening for Cox models with ultra-high-dimensional covariates.

Authors:  Sihai Dave Zhao; Yi Li
Journal:  J Multivar Anal       Date:  2012-02-01       Impact factor: 1.473

Review 2.  Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Alexander Scarth Watson; Monika Mortensen; Anna Katharina Simon
Journal:  Cell Cycle       Date:  2011-06-01       Impact factor: 4.534

3.  Reproducibility, fidelity, and discriminant validity of mRNA amplification for microarray analysis from primary hematopoietic cells.

Authors:  Liang Li; Joe Roden; Bruce E Shapiro; Barbara J Wold; Smita Bhatia; Stephen J Forman; Ravi Bhatia
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

4.  Going from genes to proteins in myelodysplastic syndromes.

Authors:  Arnold Ganser; Michael A Morgan; Eva M Weissinger
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-19       Impact factor: 11.205

Review 5.  The inflammatory microenvironment in MDS.

Authors:  Lili Yang; Yaqin Qian; Erika Eksioglu; Pearlie K Epling-Burnette; Sheng Wei
Journal:  Cell Mol Life Sci       Date:  2015-02-08       Impact factor: 9.261

Review 6.  Stem and progenitor cell alterations in myelodysplastic syndromes.

Authors:  Aditi Shastri; Britta Will; Ulrich Steidl; Amit Verma
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

7.  Induction of myelodysplasia by myeloid-derived suppressor cells.

Authors:  Xianghong Chen; Erika A Eksioglu; Junmin Zhou; Ling Zhang; Julie Djeu; Nicole Fortenbery; Pearlie Epling-Burnette; Sandra Van Bijnen; Harry Dolstra; John Cannon; Je-in Youn; Sarah S Donatelli; Dahui Qin; Theo De Witte; Jianguo Tao; Huaquan Wang; Pingyan Cheng; Dmitry I Gabrilovich; Alan List; Sheng Wei
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

Review 8.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

9.  Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes.

Authors:  David P Steensma; Jessemy D Neiger; Julie C Porcher; J Jonathan Keats; P Leif Bergsagel; Thomas R Dennis; Ryan A Knudson; Robert B Jenkins; Rafael Santana-Davila; Rajiv Kumar; Rhett P Ketterling
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

10.  Ras-proximate-1 GTPase-activating protein and Rac2 may play pivotal roles in the initial development of myelodysplastic syndrome.

Authors:  Xuejun Shao; Meihua Miao; Xiaofei Qi; Zixing Chen
Journal:  Oncol Lett       Date:  2012-05-30       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.